Evidence map›Paper›PMID 39071979›Full record

ArticleNeurotrauma reports2024

Elevated Autoantibodies to the GluA1 Subunit of the AMPA Receptor in Blood Indicate Risk of Cognitive Impairment in Contact Sports Athletes, Irrespective of Concussion.

Christopher Bailey, Daniel Soden, Joseph Maroon, Warren Selman, Christopher Tangen, John Gunstad, Susannah Briskin, Shana Miskovsky, Emiko Miller, Andrew A Pieper

Abstract read
In one paragraph

Article in Neurotrauma reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christopher BaileyDepartment of Neurology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-0237-110X
Daniel SodenUniversity Hospitals Sports Medicine Concussion Center, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA.
Joseph MaroonDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Warren SelmanDepartment of Neurology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Christopher TangenDepartment of Neurology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
John GunstadDepartment of Psychological Sciences, Kent State University, Kent, Ohio, USA.
Susannah BriskinDepartment of Neurology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Shana MiskovskyDepartment of Neurology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Emiko MillerBrain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Andrew A PieperBrain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

Funding

Translational Therapeutics CoreP30AG062428 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI LEVERENZ, JAMES BRUCE · 2019 to 2020
$5.0M
The Alzheimer's Disease Translational Data Science Training ProgramT32AG071474 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI BUSH, WILLIAM S · 2021 to 2025
$1.1M
BLRD VA I01 BX005976NIA NIH HHS P30 AG062428NIA NIH HHS T32 AG071474
6 · The paper itself

Abstract

To address the need for objective tests of concussion in athletes, we conducted a prospective clinical study in National Collegiate Athletic Association athletes of the relationship between neurocognitive performance and blood levels of the GluA1 subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor peptides and autoantibodies to GluA1. Specifically, we compared 44 contact sport athletes to 16 noncontact sport athletes, with Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), as well as blood sample collection, before the start of the season and at the end of the season. Contact sport athletes exhibited significantly elevated serum GluA1 autoantibodies at the end of season, compared with preseason levels, irrespective of whether they sustained a concussion. Noncontact sport athletes showed no change in serum GluA1 autoantibodies, and neither group showed differences in GluA1 peptides. Amongst contact-sport athletes, the 'high GluA1 autoantibody group' (≥4 ng/mL) displayed impaired reaction time, a measure of cognitive impairment, while the 'low GluA1 autoantibody group' (<4 ng/mL) displayed normal reaction time. Our results reveal that contact sport athletes are at risk for developing cognitive impairment even without sustaining a diagnosed concussion and that serum GluA1 autoantibodies provide a blood-based biomarker of this risk. This could guide future studies on the differing susceptibility to cognitive impairment in contact sport athletes and facilitate efficient allocation of resources to contact sport athletes identified as having increased risk of developing cognitive impairment.

Indexed as

AMPARcognitionconcussioncontact sportsfluid biomarkerGluA1reaction time

Identifiers

PMID39071979
PMCPMC11271151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.